Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

  • In development
  • GID-TA11674
  • Expected publication date: TBC

Documents

Documents created during the development process.

Declaration of interests

Declaration of interests

Committee meetings

  • Committee meeting

  • Committee meeting: 2

Invitation to participate

Notes